Follow us on:

EDX Medical Group’s Prostate Cancer ‘Super Test’ Aims to Revolutionise Early Detection (Video)

A ground-breaking test from EDX Medical Group plc (AQSE:EDX) could transform prostate cancer screening. With over 100 biomarkers and a patented algorithm, this new diagnostic tool aims for near-perfect accuracy—far surpassing traditional PSA tests. Founder and Chief Scientific Officer, Professor Sir Chris Evans, explains how this innovation could catch cancer at its earliest stages, potentially saving countless lives.

EDX is poised for major developments, with upcoming product launches, regulatory approvals, and expansion plans in key global markets.

EDX Medical Group is a UK-based diagnostics company focused on personalised treatment for cancer, cardiovascular, and infectious diseases.

Share on:

You might also enjoy reading EDX Medical appoints Eric Vick as Chief Commercial Officer

Find more news, interviews, share price & company profile here for:EDX Medical Group Plc

Other Interviews

EDX Medical Group: Innovating Digital Diagnostics and Cancer Testing (VIDEO) June 24, 2024

More News

EDX Medical develops new ‘super test’ for prostate cancer February 17, 2025
EDX Medical strengthens shareholder value by cancelling legacy warrants November 1, 2024
EDX Medical receives support from high net worth, experienced healthcare investor October 23, 2024
EDX Medical Chairman and Founder provide shareholder update September 9, 2024
EDX Medical appoints Eric Vick as Chief Commercial Officer September 5, 2024
EDX Medical publishes Annual Report and Notice of AGM September 4, 2024
EDX Medical signs distribution agreement with Caris Life Sciences September 2, 2024
EDX Medical partners with Oxford University to enhance cancer drug safety testing August 23, 2024
EDX Medical Group participating in “The Pub Test” Investor Evening July 12, 2024
EDX Medical Group exclusive distribution agreement with Curesponse Ltd to market the cResponse™ cancer assay June 26, 2024

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2025 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.